These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2918 related articles for article (PubMed ID: 20107219)

  • 1. Alzheimer's disease.
    Querfurth HW; LaFerla FM
    N Engl J Med; 2010 Jan; 362(4):329-44. PubMed ID: 20107219
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?].
    Buée L; Blum D; Bombois S; Buée-Scherrer V; Caillet-Boudin ML; Colin M; Deramecourt V; Dhaenens CM; Galas MC; Hamdane M; Humez S; Maurage CA; Pasquier F; Sablonnière B; Schraen-Maschke S; Sergeant N
    Therapie; 2010; 65(5):401-7. PubMed ID: 21144474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase.
    Yang H; Zhuo JM; Chu J; Chinnici C; Praticò D
    Biol Psychiatry; 2010 Nov; 68(10):922-9. PubMed ID: 20570249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial dysfunction and Alzheimer's disease.
    Maruszak A; Żekanowski C
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):320-30. PubMed ID: 20624441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Estrogen: regulation of amyloid-beta protein metabolism and attenuation of amyloid-beta protein neurotoxicity].
    Zhang S; Yao T
    Sheng Li Ke Xue Jin Zhan; 2003 Jul; 34(3):197-201. PubMed ID: 14628462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis.
    Chen K; Maley J; Yu PH
    J Neurochem; 2006 Dec; 99(5):1413-24. PubMed ID: 17074066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic mechanisms in Alzheimer's disease.
    Pastorino L; Lu KP
    Eur J Pharmacol; 2006 Sep; 545(1):29-38. PubMed ID: 16904664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease. Tangle disentanglement.
    Beyreuther K; Masters CL
    Nature; 1996 Oct; 383(6600):476-7. PubMed ID: 8849716
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunocytochemical evidence that the beta-protein precursor is an integral component of neurofibrillary tangles of Alzheimer's disease.
    Perry G; Richey PL; Siedlak SL; Smith MA; Mulvihill P; DeWitt DA; Barnett J; Greenberg BD; Kalaria RN
    Am J Pathol; 1993 Dec; 143(6):1586-93. PubMed ID: 7504885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tau, amyloid and Alzheimer's disease].
    Olesen OF
    Ugeskr Laeger; 1994 Feb; 156(8):1116-7, 1121-4. PubMed ID: 8116089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular mechanisms in Alzheimer's disease].
    Coria F; Rubio I
    Rev Neurol; 1997 Jul; 25 Suppl 1():S50-4. PubMed ID: 9280667
    [No Abstract]   [Full Text] [Related]  

  • 12. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
    Saxena U
    Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the "preamyloid" of diffuse plaques in Alzheimer's disease really nonfibrillar?
    Davies CA; Mann DM
    Am J Pathol; 1993 Dec; 143(6):1594-605. PubMed ID: 8256851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease: effects of β-amyloid on mitochondria.
    Tillement L; Lecanu L; Papadopoulos V
    Mitochondrion; 2011 Jan; 11(1):13-21. PubMed ID: 20817045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-beta, BACE, and oxidative stress in Alzheimer's disease, a commentary on "The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression".
    Lee HG; Perry G; Zhu X; Nunomura A; Smith MA
    Free Radic Biol Med; 2006 Jul; 41(2):188-9. PubMed ID: 16814097
    [No Abstract]   [Full Text] [Related]  

  • 16. Secretases as therapeutic targets for Alzheimer's disease.
    Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
    Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of new therapeutics for Alzheimer's disease.
    Carter MD; Simms GA; Weaver DF
    Clin Pharmacol Ther; 2010 Oct; 88(4):475-86. PubMed ID: 20811351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease.
    Shin J
    Int J Geriatr Psychiatry; 2011 May; 26(5):546-8. PubMed ID: 21446001
    [No Abstract]   [Full Text] [Related]  

  • 19. Two functions, one molecule: a metal-binding and a targeting moiety to combat Alzheimer's disease.
    Hureau C; Sasaki I; Gras E; Faller P
    Chembiochem; 2010 May; 11(7):950-3. PubMed ID: 20401891
    [No Abstract]   [Full Text] [Related]  

  • 20. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
    Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
    Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 146.